Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study

被引：1

作者：

le Coutre, Philipp D. ^{[1
]}

Turkina, Anna ^{[2
]}

Kim, Dong-Wook ^{[3
]}

Ceglarek, Bernadeta ^{[4
]}

Alimena, Giuliana ^{[5
]}

Al-Ali, Haifa Kathrin ^{[6
]}

Shen, Zhixiang ^{[7
]}

Jootar, Saengsuree ^{[8
]}

Smith, Graeme ^{[9
]}

De Souza, Carmino Antonio ^{[10
,11
]}

Dorlhiac-Llacer, Pedro Enrique ^{[12
]}

Rizzieri, David A. ^{[13
]}

Szczudlo, Tomasz ^{[14
]}

Berton, Myriam ^{[15
]}

Wang, Jim ^{[16
]}

Wang, Si-Tien ^{[17
]}

Nicolini, Franck Emmanuel ^{[18
]}

机构：

[1] Humboldt Univ, Charite, Dept Hematol & Oncol, Berlin, Germany

[2] Minist Publ Hlth Russia, Hematol Res Ctr, Moscow, Russia

[3] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea

[4] Inst Hematol & Transfufzjol, Warsaw, Poland

[5] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Rome, Italy

[6] Univ Leipzig, Dept Hematol Oncol, Leipzig, Germany

[7] Shanghai Ruijin Hosp, Shanghai, Peoples R China

[8] Mahidol Univ, BMT Program, Ramathibodi Hosp, Bangkok 10700, Thailand

[9] Dept Haematol, Leeds, W Yorkshire, England

[10] Univ Estadual Campinas, Hematol & Hemotherapy Ctr, Sao Paulo, Brazil

[11] Univ Estadual Campinas, Hematol & Hemotherapy Ctr, Campinas, SP, Brazil

[12] FMUSP, Hosp Clin, Sao Paulo, Brazil

[13] Duke Univ, Med Ctr, Durham, NC USA

[14] Novartis Pharmaceut, Florham Pk, NJ USA

[15] Novartis Pharmaceut, Basel, Switzerland

[16] Novartis Pharmaceut, E Hanover, NJ USA

[17] Anal Grp Inc, Boston, MA USA

[18] Hop Edouard Herriot, Lyon, France

来源：

BLOOD | 2009年 / 114卷 / 22期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1272 / 1273

页数：2

共 50 条

[1] EXPANDING NILOTINIB ACCESS IN CLINICAL TRIALS (ENACT) STUDY IN ADULT PATIENTS WITH IMATINIB-RESISTANT OR INTOLERANT CHRONIC MYELOID LEUKEMIA (CML): UPDATED SAFETY ANALYSIS
Nicolini, F.
Alimena, G.
Shen, Z.
Al-Ali, H. -K
Turkina, A.
Smith, G.
Pasquini, R.
Jootar, S.
Hsu, Y.
Veronese, M. L.
Powell, B.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 53 - 53
[2] Impact of Prior Therapy and Suboptimal Response to Imatinib On the Efficacy and Safety of Nilotinib Among 1,422 Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): Sub-Analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study
Nicolini, Franck Emmanuel
Kim, Dong-Wook
Ceglarek, Bernadeta
Turkina, Anna
Alimena, Giuliana
Al-Ali, Haifa Kathrin
Shen, Zhixiang
Jootar, Saengsuree
Smith, Graeme
De Souza, Carmino Antonio
Dorlhiac-Llacer, Pedro Enrique
Rizzieri, David A.
Szczudlo, Tomasz
Berton, Myriam
Wang, Jim
Bieri, Christine
le Coutre, Philipp D.
BLOOD, 2009, 114 (22) : 866 - 867
[3] EXPANDING NILOTINIB ACCESS IN CLINICAL TRIALS (ENACT) STUDY IN ADULT PATIENTS WITH IMATINIB-RESISTANT OR-INTOLERANT CHRONIC MYELOID LEUKEMIA (CML): FINAL SAFETY ANALYSIS OF 117 CHINESE CML PATIENTS
Shen, Z.
Huang, X.
Meng, F.
Wang, J.
Liu, T.
Hu, J.
Wang, J.
Zhao, Y.
Woodman, R.
Zou, P.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 348 - 349
[4] Expanding nilotinib access in clinical trials (ENACT) study in adult patients (Pts) with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in blast crisis (BC), accelerated phase (AP), or chronic phase (CP): Preliminary safety analysis
Nicolini, Franck
Alimena, Giuliana
Al-Ali, Haifa-Kathrin
Zaritskey, Andrey
Shen, Zhixiang
Jootar, Saengsuree
Smith, Graeme
Hsu, Yanzhi
Veronese, Maria Luisa
Rizzieri, David A.
BLOOD, 2007, 110 (11) : 870A - 870A
[5] FINAL SAFETY ANALYSIS OF 1,793 CML PATIENTS FROM ENACT (EXPANDING NILOTINIB ACCESS IN CLINICAL TRIALS) STUDY IN ADULT PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA
Nicolini, F. E.
Alimena, G.
Al-Ali, H. K.
Turkina, A. T.
Shen, Z.
Jootar, S.
Smith, G.
De Souza, C.
Wang, J.
Berton, M.
Szczudlo, T.
Rizzieri, D. A.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 255 - 256
[6] NILOTINIB SAFETY AND RESPONSES ANALYSIS IN RUSSIAN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) FROM ENACT(EXPANDING NILOTINIB ACCESS IN CLINICAL TRIALS) STUDY
Turkina, A.
Khoroshko, N.
Bakirov, A.
Korobkin, A.
Pospelova, T.
Rossiev, V.
Shatokhin, Y.
Silin, A.
Zaritsky, A.
Kravchenko, E.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 534 - 534
[7] Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis
Nicolini, Franck E.
Masszi, Tamas
Shen, Zhixiang
Gallagher, Neil J.
Jootar, Saengsuree
Powell, Bayard L.
Dorlhiac-Llacer, Pedro Enrique
Zheng, Ming
Szczudlo, Tomasz
Turkina, Anna
LEUKEMIA & LYMPHOMA, 2012, 53 (05) : 907 - 914
[8] Patterns and Management of Selected Adverse Events of Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.
le Coutre, Philipp D.
Ceglarek, Bernadeta
Turkina, Anna
Kim, Dong-Wook
Alimena, Giuliana
Al-Ali, Haifa Kathrin
Shen, Zhixiang
Jootar, Saengsuree
Smith, Graeme
De Souza, Carmino Antonio
Rizzieri, David A.
Szczudlo, Tomasz
Berton, Myriam
Wang, Jim
Dial, Ellison
Nicolini, Franck Emmanuel
BLOOD, 2009, 114 (22) : 457 - 458
[9] EXPANDING NILOTINIB ACCESS IN CLINICAL TRIALS (ENACT) STUDY IN ADULT PATIENTS (PTS) WITH IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA (CML): SUBGROUP ANALYSIS OF PATIENTS WHO FAILED PRIOR DASATINIB THERAPY
Nicolini, F. E.
Alimena, G.
Al-Ali, H. K.
Turkina, A. T.
Shen, Z.
Jootar, S.
Smith, G.
Conchon, M.
Wang, J.
Berton, M.
Szczudlo, T.
Rizzieri, D. A.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 257 - 257
[10] Expanding Nilotinib Access in Clinical Trials (ENACT) An Open-Label, Multicenter Study of Oral Nilotinib in Adult Patients With Imatinib-Resistant or Imatinib-Intolerant Philadelphi Chromosome-Positive Chronic Myeloid Leukemia in the Chronic Phase
Nicolini, Franck E.
Turkina, Anna
Shen, Zhi-Xiang
Gallagher, Neil
Jootar, Saengsuree
Powell, Bayard L.
De Souza, Carmino
Zheng, Ming
Szczudlo, Tomasz
le Coutre, Philipp
CANCER, 2012, 118 (01) : 118 - 126

← 1 2 3 4 5 →